| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Outline of Final Research Achievements |
We showed that SS-20, a newly developed compound that possesses mitochondrial protective properties, can prevent the development of peripheral neuropathies in mice induced by oxaliplatin and paclitaxel, both widely used chemotherapy agents to treat cancer patients. These results suggest that peripheral neuropathies induced by multiple chemotherapy agents likely possess a common mechanism, i.e. mitochondrial injury. Furthermore, these results suggest that SS-20 may be a promising candidate for the prevention of chemotherapy-induced peripheral neuropathy.
|
